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Background: Infection with Gram-negative bacteria is associated with increased morbidity
and  mortality. The aim of this study was to evaluate the predictors of 7- and 30-day mortality
in  pediatric patients in an intensive care unit with cancer and/or hematologic diseases and
Gram-negative  bacteria infection.
Methods: Data were collected relating to all episodes of Gram-negative bacteria infection
that  occurred in a pediatric intensive care unit between January 2009 and December 2012,
and  these cases were divided into two groups: those who were deceased seven and 30 days
after  the date of a positive culture and those who survived the same time frames. Variables
of  interest included age, gender, presence of solid tumor or hematologic disease, cancer
status,  central venous catheter use, previous Pseudomonas aeruginosa infection, infection
by  multidrug resistant-Gram-negative bacteria, colonization by multidrug resistant-Gram-
negative  bacteria, neutropenia in the preceding seven days, neutropenia duration ≥3 days,
healthcare-associated  infection, length of stay before intensive care unit admission, length
of  intensive care unit stay >3 days, appropriate empirical antimicrobial treatment, deﬁnitive
inadequate  antimicrobial treatment, time to initiate adequate antibiotic therapy, appro-
priate  antibiotic duration ≤3 days, and shock. In addition, use of antimicrobial agents,
corticosteroids,  chemotherapy, or radiation therapy in the previous 30 days was noted.
Results: Multivariate logistic regression analysis resulted in signiﬁcant relationship between
shock  and both 7-day mortality (odds ratio 12.397; 95% conﬁdence interval 1.291–119.016;
p  = 0.029) and 30-day mortality (odds ratio 6.174; 95% conﬁdence interval 1.760–21.664;
p  = 0.004), between antibiotic duration ≤3 days and 7-day mortality (odds ratio 21.328;
95%  conﬁdence interval 2.834-160.536; p = 0.003), and between colonization by multidrug
resistant-Gram-negative bacteria and 30-day mortality (odds ratio 12.002; 95% conﬁdence
interval  1.578–91.286; p = 0.016).Conclusions: Shock was a p
resistant-Gram-negative b
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Introduction
Children undergoing treatment for malignancy have an
excellent  chance of survival, with an overall survival rate
approaching 75%.1 In most cases, children who die following
treatment for cancer do so as a result of their disease. However,
despite  signiﬁcant improvements in supportive care, approxi-
mately  16% of the deaths within ﬁve years following diagnosis
are  due to complications of therapy.1 Infection continues to
be  one such life-threatening complication in immunocompro-
mised children.1
With recent advances in cancer treatments and improve-
ments in critical care, an increasing number of patients with
hematologic  malignancies are being admitted to intensive
care  units (ICU).2 Despite the associated improvements in out-
comes,  mortality remains high in critically ill patients with
hematologic malignancies, particularly in the presence of ICU-
acquired  nosocomial infections.2 In addition, infection results
in  ICU admission in cancer patients.
Oncologic patients are at a greater risk of developing sep-
sis  and nosocomial infections as a consequence of a number
of  mechanisms, including immunosuppression related to the
disease  itself and to aggressive treatments, such as combined
regimens of chemotherapy and radiation therapy, high dose
steroids,  and hematopoietic stem cell transplantation.3 More-
over,  despite recent improvements in survival rates, sepsis in
patients with cancer remains associated with high morbidity,
mortality, costs, and use of ICU resources, and information on
this topic is limited.3
Research has previously focused on adult patients with
cancer.  Little is known regarding the predictors of 7- and
30-day  mortality related to Gram-negative bacterial (GNB)
infection  in children with cancer who are hospitalized in the
ICU.  Therefore, this study aimed at evaluating the predictors
of  7- and 30-day mortality risk in children with cancer and/or
hematologic diseases who  were  also infected with GNB.
Patients  and  methods
Study  design
We  performed a case–control study in the pediatric ICU of
the  National Cancer Institute (INCA), Rio de Janeiro, Brazil,
which  is an exemplary tertiary oncology public hospital. The
6-bed  pediatric ICU admits only patients with solid tumors and
hematologic  malignancies. Admission to the ICU is not gen-
erally  permitted for palliative care. However, some patients
may  be admitted while a full assessment of the extent of their
cancer  and therapeutic options is still ongoing.
We collected data related to all GNB episodes that occurred
between January 2009 and December 2012 in patients aged less
than 18 years, who were  hospitalized for >24 h in the pediatric
ICU.  The study was  approved by the ethics committee of the
Fluminense  Federal University.GNB  infections were  divided into two groups by time and
survival  status: patients who were deceased and those who
survived  seven and 30 days after the date of a positive culture.
At  each time period, the patients were from the same unit 1 4;1  8(6):591–599
and  had infections that occurred at the same time and at the
same  sites.
The  following data were collected: age, gender, presence
of  solid tumor or hematologic disease, cancer status, central
venous  catheter use, previous Pseudomonas aeruginosa infec-
tion,  healthcare-associated infection, infection by multi-drug
resistant (MDR)-GNB, colonization by MDR-GNB (assessed
using  a rectal swab or stool culture), neutropenia in the preced-
ing  seven days, neutropenia duration ≥3 days, length of stay
before  ICU admission, length of ICU stay >3 days, appropri-
ate  empirical antimicrobial treatment, deﬁnitive inadequate
antimicrobial treatment, appropriate antibiotic duration ≤3
days,  the time to initiate adequate antibiotic therapy, and
shock  (within two days before or after the date of a posi-
tive  culture). In addition, the use of any of the following in
the  previous 30 days was  noted: antimicrobial agents, corti-
costeroids,  chemotherapy, or radiation therapy. Colonization
with  antibiotic-resistant GNB was detected via weekly routine
surveillance  (nasal and rectal swabs).
Deﬁnition  of  terms
Death within seven days or 30 days after the date of a positive
culture  was considered as 7- and 30-day mortality, respec-
tively.  An episode of infection was  deﬁned as the isolation of
GNB  from three days before the date of pediatric ICU admis-
sion  to the last day of hospitalization in the pediatric ICU,
from  cultures of blood, urine, stools, broncho-alveolar lavage,
tracheal  aspirate, cerebrospinal ﬂuid, or catheter tip, in the
presence  of associated, compatible clinical signs or symptoms.
The  tracheal aspirate was  collected from endotracheal tubes
and  tracheostomies of patients who underwent mechanical
ventilation. The diagnostic criteria for pneumonia included
purulent tracheobronchial secretion and new pathogenic
bacteria isolated from tracheal aspirate or broncho-alveolar
lavage in addition to two or more  of the following criteria:
fever  >38 ◦C; leukocytes >12,000 cells/mL or <4000 cells/mL; a
new and persistent (>48 h) inﬁltrate on chest radiograph; new
onset  or worsening cough, dyspnea, or tachypnea; and declin-
ing  gas exchange. Catheter cultures were performed when a
catheter was removed for suspected intravascular catheter-
related  infection, if the patient had unexplained sepsis or
erythema  overlying the catheter insertion site, or if there was
purulence  at the catheter insertion site. The end of the infec-
tion  episode was  the date when the infection was  considered
to  be resolved by the medical team.
The presence of extended spectrum beta-lactamase (ESBL)-
producing  Enterobacteriaceae; microorganisms with intrinsic
resistance mechanisms such as S. maltophilia and Eliz-
abethkingia meningoseptica; carbapenem-resistant GNB; or
strains  of A. baumannii were  considered as MDR-GNB infec-
tion.  Polymicrobial infection involved the isolation of more
than  one pathogen from a culture sample.
Neutropenia was  deﬁned as an absolute neutrophil count
<500  neutrophils/mm3 in blood samples. Shock was deﬁned as
arterial hypotension requiring vasoactive drugs.Initial antimicrobial treatment was considered inappro-
priate if the treatment regimen did not include at least one
antibiotic  active in vitro against the microorganism. It was  also
considered inappropriate when the antibiotic treatment was
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Table 1 – Characteristics of pediatric patients with Gram-negative bacterial infection based on rectal swab or stool culture.
With swab or culture







Gender (boys) 42 (50.6) 10 (55.6) 0.792
Age (years)a 5 (0.2–18) 12 (1–17) 0.023
MDR-GNB 42 (50.6) 6 (33.3) 0.298
Cancer status (controlled) 15 (18.1) 5 (27.8) 0.262
Hematologic diseases 21 (25.3) 3 (16.7) 0.551
Previous antibiotic therapyb 75 (90.4) 14 (77.8) 0.219
Central venous catheter 76  (91.6) 17  (94.4) 1.000
Use of corticosteroidsb 75 (90.4) 17  (94.4) 1.000
Neutropeniac 23 (27.7) 4 (22.2) 0.774
Neutropenia duration ≥3 days 14 (16.9) 4 (22.2) 0.590
Healthcare-associated infection (from ward and pediatric ICU) 68 (82.0) 14 (77.8) 0.683
Length of stay before ICU admissiona 2 (0–89) 2.5 (0–14) 0.844
Length of ICU stay >3 days 42 (50.6) 8 (44.4) 0.636
Chemotherapy/radiation therapyb 61 (73.5) 11 (61.1) 0.389
Previous episode of Pseudomonas aeruginosa infectionb 13 (15.7) 4 (22.2) 0.497
Inappropriate initial antimicrobial treatment 37 (44.6) 9 (50) 0.795
Deﬁnitive inadequate antimicrobial treatment 3 (3.6) 2 (11.1) 0.216
Time to initiate adequate antibiotic therapy (days)a 1 (0–10) 0 (0–7) 0.908
Shock 30 (36.1) 5 (27.8) 0.592
7-day mortality 6 (7.2) 2 (11.1) 0.630
30-day mortality 19 (22.9) 2 (11.1) 0.348
ICU, intensive care unit; MDR-GNB, multi-drug resistant-gram-negative bacteria.



























sIn the 30 days prior to the positive culture for gram-negative bacte
c In the 7 days prior to the positive culture for gram-negative bacteri
ot started on the date of the positive culture. Furthermore,
n  patients from whom ESBL-producing bacteria had grown
n  cultures, treatment with penicillin and cephalosporins was
onsidered  inappropriate. Deﬁnitive inadequate antimicrobial
reatment was  deﬁned when the patient did not receive any
ntibiotic  active in vitro against the microorganism during the
eriod  of infection.
icrobiological  studies
acterial identiﬁcation was  performed by the INCA micro-
iology  laboratory using the Vitek automated method
Bio-Merieux, Inc., France) with manual conﬁrmation of bacte-
ial  isolates and antimicrobial resistance, as per the standards
ecommended by the Clinical Laboratory Standard Institute
CLSI).
tatistical  analysis
tatistical analysis was  conducted using SPSS v17 (SPSS Inc;
hicago,  Illinois, USA). Continuous variables were  compared
sing  Mann–Whitney U test and Student’s t-test. Categori-
al  variables were  analyzed using two-tailed Chi-square test.
dds  ratios (OR) and 95% conﬁdence intervals (CI) were cal-
ulated.  Separate multivariate logistic regression analyses
ncluded  the factors potentially associated with 7- or 30-day
ortality  based on statistically signiﬁcant variables in univari-
te  analyses. A value of p < 0.05 was  considered statistically
igniﬁcant.Results
In the period from January 1, 2009 to December 31, 2012,
there  were 101 episodes of GNB infection in 76 patients out of
765  total admissions to the pediatric ICU. Of these episodes,
47  (46.5%) were  related to MDR-GNB infection. Eight (10.5%)
patients  presented with >1 episode of non-MDR-GNB infec-
tion,  4 (5.3%) patients presented with >1 episode of MDR-GNB
infection, and 8 (10.5%) patients presented with separate
episodes of MDR-GNB and non-MDR-GNB infections. A single
GNB  was  isolated in 98 (97.0%) episodes, and in three (3.0%)
episodes,  two isolates were recovered. All-cause mortality rate
was 7.9% (8/101) on day 7 and 20.8% (21/101) on day 30.
During  the study period, 18 episodes did not have a related
rectal  swab or stool culture (two deceased and 16 survivors);
however, the characteristics, except for age, were  similar
between these patients and those with a swab or culture
(Table 1).
Fig.  1 provides the frequency of each pathogen in the
patients with 7-day mortality. The most frequently occurring
pathogens in these patients were  A. baumanii (37.5%) and Pseu-
domonas  (25.0%). In this group, the bacteria were  isolated from
the  sites as follows: 3 (37.5%) from a combination of tracheal
aspirate  and blood cultures, 3 (37.5%) from blood cultures,
1  (12.5%) from tracheal aspirate culture, and 1 (12.5%) from
a  combination of catheter tip, tracheal aspirate, and blood
cultures.  There was concordance between the isolate microor-
ganisms  when the GNB were isolated from a combination of
different  culture sites.

















Fig. 1 – Gram-negative bacterial isolates detected in the patients with Gram-negative bacterial infections and 7-day










































Fig. 2 – Gram-negative bacterial isolates detected in the patients with Gram-negative bacterial infections who survived at
seven days after the positive culture in a pediatric intensive care unit (n = 93).
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Table 2 – Demographic and clinical variables related to 7-day mortality in patients with Gram-negative bacterial
infections in a pediatric intensive care unit (ICU), analyzed using univariate and multivariate logistic regression.
Univariate logistic regression analysis Multivariate logistic
regression  analysis
Survivors
n  = 93
n (%)
Non-survivors
n  = 8
n (%)
OR  95% CI p value OR 95% CI p value
Gender (boys) 46 (49.5) 6  (75) 3.065 0.588–15.979  0.184 – – –
Age (years)a 6 (0.2–17) 13 (1–18) 1.149 0.994–1.328 0.060 – – –
Hematologic diseases 21 (22.6) 3 (37.5) 2.057 0.454–9.327 0.350 – – –
Cancer status (controlled) 19 (20.4) 1 (12.5) 0.556 0.064–4.801 0.594 – – –
Previous antibiotic therapyb 82 (88.2) 7 (87.5) 0.939 0.105–8.372 0.955 – – –
Central venous catheter 86 (92.5) 7 (87.5) 0.570 0.061–5.312 0.621 – – –
Use of corticosteroidsb 84 (90.3) 8 (100) 1.539 0.000 0.999 – – –
Neutropeniac 22 (23.7) 5 (62.5) 5.379 1.189– 24.327 0.029 – – 0.500
Neutropenia duration ≥3 days 15 (16.1) 3 (37.5) 3.120 0.673–14.471 0.146 – – –
Healthcare-associated infection
(from  ward and pediatric ICU)
76 (81.7) 6 (75.0) 0.671 0.125–3.617 0.643 – – –
Length of stay before ICU
admissiona
2 (0–89) 1 (0–7) 0.926 0.795–1.078 0.320 – – –
Length of ICU stay >3 days 47 (50.5) 3 (37.5) 1.703 0.385–7.541 0.492 – – –
Chemotherapy/radiation therapyb 65 (69.9) 7 (87.5) 3.015 0.354– 25.671 0.312 – – –
Previous episode of Pseudomonas
aeruginosa  infectionb
16 (17.2) 1 (12.5) 0.688 0.79–5.982 0.734 – – –
Colonization by MDR-GNB 22/77 (28.6) 3/6 (50) 1.091 0.163–7.305 0.929 – – –
Inappropriate initial antimicrobial
treatment
52  (55.9) 3 (37.5) 0.473 0.107–2.096 0.324 – – –
Time to initiate adequate
antibiotic  therapy (days)a
1 (0–10) 0 (0–4) 0.704 0.347–1.431 0.333 – – –
Deﬁnitive inappropriate antibiotic
treatment
3  (3.2) 2 (25) 10.000 1.393–71.766 0.022 – – 0.457
Antibiotic duration ≤3 days 3 (3.2) 4 (50) 30 4.954–181.686 <0.001 21.328 2.834–160.536 0.003
Shock 28 (30.1) 7  (87.5) 16.250  1.909–138.340 0.011 12.397 1.291–119.016 0.029
Infection by MDR-GNB 42 (45.2) 5 (62.5) 2.024 0.457–8.966 0.353 – – –























mReported as median (range).
b In the 30 days prior to the positive culture for gram-negative bacte
c In the 7 days prior to the positive culture for gram-negative bacteri
Fig. 2 provides the frequency of each pathogen in the
atients who  survived for at least 7 days. In these patients,
he  most frequent sites of bacterial isolation were  tracheal
spirate  (n = 38, 40.9%), blood culture (n = 15, 16.1%), and urine
ulture  (n = 14, 15.1%).
The most frequently occurring underlying diseases in
he  patients with 7-day mortality were  rhabdomyosarcoma
25%), acute lymphoblastic leukemia (12.5%), acute myeloid
eukemia  (12.5%), osteosarcoma (12.5%), central nervous sys-
em tumor (12.5%), retinoblastoma (12.5%), and non-Hodgkin’s
ymphoma (12.5%). Only one patient in this group had under-
one  bone marrow transplantation. Regarding cancer status,
0.0%  of the patients were recently diagnosed, 37.5% had
xperienced disease progression or relapse, and 12.5% had
ontrolled  disease.
Among  patients who  survived seven days after GNB infec-
ion,  the most frequently occurring diseases were central
ervous system tumor (38.7%), neuroblastoma (14%), and non-
odgkin’s lymphoma (9.7%). Regarding cancer status, 50.5% of
he  patients were  recently diagnosed, 29.0% had experienced
isease progression or relapse, and 20.4% had controlled dis-
ase.  None of the patients in this group had undergone bone
arrow  transplantation.Among  patients with 7-day mortality, there were  two
(25.0%)  episodes of infection at admission (acquired at home),
three  (37.5%) episodes of healthcare-associated infections
acquired at the ward,  and three (37.5%) episodes of healthcare-
associated infection acquired at the pediatric ICU. Of patients
who  survived seven days after GNB infection, there were
17  (18.3%) episodes of infection at admission (acquired at
home),  19 (20.4%) episodes of healthcare-associated infection
acquired  at the ward,  and 57 (61.3%) episodes of healthcare-
associated infection acquired at the pediatric ICU.
Table 2 provides the univariate and multivariate logis-
tic  regression risk factor analyses for the 7-day mortality.
Shock, neutropenia, antibiotic duration ≤3 days, and deﬁnitive
inappropriate antibiotic use were associated with 7-day mor-
tality  in univariate analyses. Shock (p = 0.029) and antibiotic
duration ≤3 days (p = 0.003) were  variables that remained sig-
niﬁcantly  associated with 7-day mortality in the multivariate
logistic regression analysis.
Fig.  3 provides the frequency of each pathogen in
patients with 30-day mortality. The most frequently occurring
pathogens in these patients were  Pseudomonas (28.6%), E. coli
(23.8%),  and Acinetobacter (23.8%). In this group, the most fre-
quent  sites of bacterial isolation were tracheal aspirate (n = 5,























Fig. 3 – Gram-negative bacterial isolates detected in the patients with Gram-negative bacterial infections and 30-day
ediamortality (death within 30 days of the positive culture) in a p
23.8%), blood culture (n = 5, 23.8%), combination of tracheal
aspirate and blood culture (n = 3, 14.3%) and urine culture (n = 3,
14.3%).
The most frequently occurring underlying diseases in the
patients  with 30-day mortality were  central nervous system
tumor  (28.6%), acute lymphoblastic leukemia (14.3%), acute
myeloid  leukemia (9.5%), rhabdomyosarcoma (9.5%), prim-
itive  neuroectodermal tumor (9.5%), retinoblastoma (9.5%),
non-Hodgkin’s lymphoma (9.5%), neuroblastoma (4.8%), and
osteosarcoma  (4.5%). Only one patient in this group had under-
gone  bone marrow transplantation. Regarding cancer status,
47.6%  of the patients were  recently diagnosed, 47.6% had
experienced disease progression or relapse, and 4.8% had con-
trolled disease.
In  the patients who survived 30 days after GNB infection,
the  most frequently occurring underlying diseases were  cen-
tral  nervous system tumor (38.7%), neuroblastoma (15.0%),
and  non-Hodgkin’s lymphoma (10.0%). Regarding cancer sta-
tus, 51.3% of the patients were recently diagnosed, 25.0% had
experienced  disease progression or relapse, and 23.8% had
controlled  disease. None of the patients in this group had
undergone bone marrow transplantation.
In the patients with 30-day mortality, there were ﬁve
(23.8%) episodes of infection at admission (acquired at home),
6  (28.6%) episodes of healthcare-associated infection acquired
at  the ward,  and 10 (47.6%) episodes of healthcare-associated
infection acquired at the pediatric ICU. In the patients who
survived  30 days after GNB infection, there were 14 (17.5%)
episodes of infection at admission (acquired at home), 16
(20.0%)  episodes of healthcare-associated infection acquired
at  the ward,  and 50 (62.5%) episodes of healthcare-associated
infection acquired at the pediatric ICU.tric intensive care unit (n = 21).
Fig. 4 provides the frequency of each underlying diseases
among patients who survived 30 days. In these patients, the
most  frequent sites of bacterial isolation were  tracheal aspi-
rate  (n = 34, 42.5%), blood culture (n = 13, 16.3%), and urine
culture  (n = 11, 13.8%).
The results of the univariate and multivariate logistic
regression analyses are provided in Table 3. Only shock
(p  = 0.004) and colonization by MDR-GNB (p = 0.016) were  sig-
niﬁcantly  associated with 30-day mortality in the multivariate
logistic  regression.
Discussion
Research has previously focused on adult patients, while the
sample  of the present study included critically ill pediatric
patients with cancer and GNB infection, a speciﬁc and vulnera-
ble  population of which there is little information available, in
a pediatric ICU that specializes in the management of patients
with  cancer and severe complications. Shock emerged as an
important  predictor of both 7- and 30-day mortality. Further-
more,  appropriate antibiotic duration ≤3 days was associated
with  7-day mortality, whereas colonization by MDR-GNB was
associated  with 30-day mortality. At the same time, cancer
status  was not associated with mortality, potentially owing
to  the exclusion of palliative care patients from ICU admis-
sion.  The identiﬁcation of risk factors for mortality in these
patients  with GNB infection may  assist with the prevention
of  future infections and planning of appropriate management
strategies.
This  is particularly important given that sepsis continues
to  be a common complication in patients with cancer and is










































Fig. 4 – Gram-negative bacterial isolates detected in the patients with Gram-negative bacterial infections who  survived 30


























eesponsible for almost half of ICU admissions in nonscheduled
urgical patients.3 Oncologic patients represent a considerable
roportion of septic patients with up to one in six severely sep-
ic  patients having malignancies; these patients have a 30%
igher  risk of death when compared with general patients.3
hildren with multiple organ dysfunction syndrome and sep-
is  are also at a greater risk of mortality than those without
epsis.4
The impact of appropriate empirical antimicrobial ther-
py  has not been clearly established. In the current study,
 signiﬁcant association was  not found between mortality
nd  initial appropriate antimicrobial treatment or the time
o  initiate adequate antibiotic therapy. These results support
hose  reported in previous studies indicating that antibiotic
esistance5,6 and initial appropriate antimicrobial treatment7
ay  have limited impact on mortality.
The relationship between the timeliness of adequate ther-
py  and prognosis is complex. Physicians often prescribe early
xtended-spectrum antimicrobial therapy to patients that
resent  with severe clinical conditions;5 the clinical outcome
s  inﬂuenced by disease severity and degree of virulence,3 and
atients  with serious underlying disease and septic shock are
ess likely to tolerate delays in the administration of effec-
ive  antibiotics. In contrast, antimicrobial therapy is often
elayed  in patients who do not have organ dysfunction or
or  whom there is a delay in a positive blood culture.5 In
dults  with cancer and Stenotrophomonas maltophilia infection,
very  additional day of adequate antibiotic therapy has beendemonstrated  to decrease the risk of mortality by 1.36,7 while a
retrospective cohort study suggested that every hour of delay
in  effective antibiotic administration from the second hour
after  the onset of persistent or recurrent hypotension (septic
shock)  signiﬁcantly increases hospital mortality.8 Moreover,
shock  has been associated with mortality in a number of
studies.3,5,9,10 Therefore, the delay of appropriate antibiotics
confers a greater risk of mortality in patients with shock and
inﬂuences  prognosis. The results of the current study, in addi-
tion  to those of other studies, support the signiﬁcance of
disease  severity on patient outcomes. The impact of resistant
GNB  infection on mortality also depends on the severity of the
underlying  disease, and the nature and severity of organ fail-
ure  are major determinants of outcome in critically ill patients
with  cancer.5 In the present study, the severity of the under-
lying  disease may  explain the observed association between a
short duration (≤3 days) of antibiotic administration and 7-day
mortality.  Finally, patients with early mortality never receive
antimicrobial therapy.5
However, it has also been shown that a 2–3-day delay
in  adequate antibiotic therapy has little effect on patient
mortality, potentially related to the original focus of the
infection.11 For example, poorer outcomes have been observed
in  patients with non-urinary tract infections, primarily pneu-
monia  and abdominal infections.3 In the present study,
pneumonia (38.6%, n = 39/101) and bloodstream infections
(17.8%, n = 18/101) accounted for over half of the infec-
tions (56.4%), and these infections are associated with poor
598  b r a z j i n f e c t d i s . 2 0 1 4;1  8(6):591–599
Table 3 – Demographic and clinical variables related to 30-day mortality in patients with Gram-negative bacterial
infections in a pediatric intensive care unit (ICU) analyzed using univariate and multivariate logistic regression.
Univariate logistic regression analysis Multivariate logistic
regression  analysis
Survivors





OR 95% CI p  value OR  95% CI p value
Gender (boys) 43 (53.8) 9 (42.9) 0.645 0.245–1.702 0.376 – – –
Age (years)a 6 (0.2–17) 11 (0.5–18) 1.039 0.954–1.131 0.377 – – –
Hematologic diseases 17 (21.3) 7 (33.3) 1.853 0.646–5.314 0.251 – – –
Cancer status (controlled) 19(23. 8) 1 (4.8) 0.161 0.020–1.276 0.084 – – –
Previous antibiotic therapyb 71 (88.8) 18 (85.7) 0.761 0.187–3.101 0.703 – – –
Central venous catheter 73 (91.3) 20 (95.2) 1.918 0.223–16.512 0.553 – – –
Use of corticosteroidsb 71 (88.8) 21 (100) 4.778 0.000 0.999 – – –
Neutropeniac 20 (25) 7 (33.3) 1.5 0.531–4.239 0.444 – – –
Neutropenia duration ≥3 days 13 (16.3) 5 (23.8) 1.611 0.502–5.172 0.423 – – –
Healthcare-associated infection
(from  the ward and pediatric ICU)
66 (82.5) 16 (76.2) 0.679 0.213–2.161 0.512 – – –
Length of stay before ICU
admissiona
1.5 (0–89) 2 (0–36) 0.983 0.941–1.027 0.456 – – –
Length of ICU stay >3 days 43 (53.8) 7 (33.3) 2.324 0.848–6.370 0.101 – – –
Chemotherapy/radiation therapyb 54 (67.5) 18 (85.7) 2.889 0.780–10.693 0.112 – – –
Previous episode of Pseudomonas
aeruginosa  infectionb
15 (18.8) 2 (9.5) 0.456 0.096–2.174 0.324 – – –
Colonization by MDR-GNB 14/64 (21.8) 11/19 (57.9) 6.286 1.185–33.346 0.031 12.002 1.578–91.286 0.016
Inappropriate initial antibiotic 43 (53.8) 12 (57.1) 1.147 0.435–3.025 0.781 – – –
Time to initiate adequate antibiotic
therapy  (days)a
1 (0–10) 1 (0–4) 0.955 0.735–1.242 0.733 – – –
Deﬁnitive inappropriate antibiotic
treatment
3  (3.8) 2 (9.5) 2.702 0.421–17.326 0.295 – – –
Antibiotic duration ≤3 days 3 (3.8) 4 (19) 6.039 1.236–29.509 0.026 4.758 0.764–29.645 0.095
Shock 22 (27.5) 13 (61.9) 4.284 1.563–11.742 0.005 6.174 1.760–21.664 0.004
Infection by MDR-GNB 35 (43.8) 12 (57.1) 1.714 0.649–4.525 0.276 – – –
CI, conﬁdence interval; ICU, intensive care unit; MDR-GNB, multidrug-resistant gram-negative bacteria; OR, odds ratio.
a Reported as median (range).
b In the 30 days prior to the positive culture for gram-negative bacteria.
a.c In the 7 days prior to the positive culture for gram-negative bacteri
prognoses. However, in the current study, the delay of appro-
priate  antibiotics had a limited impact on mortality, regardless
of  the focus of infection.
The  relationship between inappropriate initial empiric
antibiotic therapy and mortality may  also be affected by
several  different factors. First, inappropriate antibiotics may
have  some activity in vivo. Cephalosporin has been associated
with  treatment failure, but can be effective for Gram nega-
tive  producing ESBL infections with low minimum inhibitory
concentrations,12 with mortality occurring in only 16.6% of
patients  with serious ESBL-producing GNB infections with
cephalosporin susceptibility at a minimum inhibitory concen-
tration  of 2–8 mcg/mL that were  treated with cephalosporin.13
Piperacillin and tazobactam were no more  effective than car-
bapenem  in a recent analysis of six prospective cohorts of
patients  with bacteremia caused by ESBL-producing E. coli.9
Therefore, the use of inappropriate antibiotics may  have some
effect,  even when followed by appropriate antibiotic ther-
apy,  and a short delay (e.g., up to two days) in adjusting the
deﬁnitive  antibiotic therapy may  not impact mortality if the
antibiotic  therapy is adjusted according to the results of sus-
ceptibility  testing.10,11Furthermore, many  issues may  inﬂuence the efﬁcacy of
antibiotics. For example, in vitro success may  not translate to in
vivo effectiveness due to inadequate dosing, variable pharma-
cokinetics,  or variable penetration into affected tissues, such
as  the lungs or abscesses. Non-removal of a septic focus, such
as  an infected intravascular catheter or an intra-abdominal
abscess, may  compromise cure rates. In addition, an increas-
ingly  recognized variable that affects antibiotic efﬁcacy is the
mode  of administration. The inappropriate use of antibiotics
may  render a theoretically effective antibiotic ineffective.14
The increasing prevalence of ESBL carriage on ICU admis-
sion  raises important questions about empiric therapy policies
in  patients presenting with infection, which may  include the
use  of a carbapenem as ﬁrst-line therapy.15 Since the emer-
gence  of antibiotic resistance is associated with widespread
broad-spectrum antibiotic use, the availability of effective
treatments becomes limited without the cautious use of
carbapenems.15 Owing to the increasing difﬁculty in choosing
initial  empirical antibiotics against possible MDR-GNB, clini-
cal  interventions for infection control may  play an important
role  in decreasing the prevalence of MDR-GNB, and thereby
break  the vicious cycle.16 Reducing the incidence of MDR-GNB








































2b r a z j i n f e c t d i s .
ith multifaceted interventions may  be crucial in improving
he  outcomes related to ICU-acquired infections in developing
ountries.16
In severely ill hospitalized patients, the normal ﬂora of
he  bowel can be affected. Under these conditions, patients
re  predisposed to persistent colonization by exogenous
athogens that cause nosocomial epidemics,17 and a major
isk  factor for nosocomial infection is prior colonization.18,19
he proportion of positive surveillance cultures increases with
 longer hospital stay; therefore, it could be expected that overt
olonization  would precede bacteremia that occurs following
 prolonged ICU stay.20 It has been previously demonstrated
hat colonization by MDR-GNB is associated with poor clin-
cal  outcomes in adults,21 and the current study indicates
hat MDR-GNB might be associated with longer-term (30-day)
ortality.  It is unknown whether higher mortality among col-
nized patients with a prolonged ICU stay is related to more
evere  injuries, a greater number of interventions, or more
evere  underlying illnesses. In fact, it is possible that isolation
tself  contributes to poor clinical performance.21 However, the
wareness  of MDR-GNB colonization can lead to more  appro-
riate  antimicrobial drug use, improve patient outcomes, and
ecrease  the emergence of antimicrobial drug resistance.21
Limitations of the current study include its retrospective
esign and small sample size. Despite these, signiﬁcant dif-
erences  were  observed.
In  conclusion, a major risk factor for mortality in pediatric
ncologic patients with GNB infection is shock. Consequently,
t  is important to provide aggressive therapy.
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